Axitinib
| CAS No. | 319460-85-0 |
|---|---|
| MDL No. | MFCD09837898 |
| MF | C22H18N4OS |
| MW | 386.50 |
| InChI Key | RITAVMQDGBJQJZ-FMIVXFBMSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Axitinib is an indazole substituted at position 3 with a 2-(pyridin-2-yl)vinyl group and at position 6 with a 2-(N-methylaminocarboxy)phenylsulfanyl group. It is used for the treatment of advanced renal cell carcinoma following failure of first-line systemic therapy. Axitinib functions as an antineoplastic agent, tyrosine kinase inhibitor, and vascular endothelial growth factor receptor antagonist. It belongs to the classes of indazoles, pyridines, aryl sulfides, and benzamides.
| CAS No. | 319460-85-0 |
|---|---|
| Product Name | Axitinib |
Biological Targets
FLT1·FLT4·KDR
Associated Conditions
colorectal neoplasm·stomach neoplasm·salivary gland cancer·prostate adenocarcinoma·myelodysplastic syndrome·
* The information provided here is compiled from public sources and is for reference only.